Trial Profile
The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- 01 Apr 2022 Results published in the American Journal of Hematology
- 28 Aug 2017 New trial record